Parallel Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $801K | Buy |
4,367
+65
| +2% | +$12K | 0.01% | 557 |
|
|
2025
Q4 | $757K | Buy |
4,302
+79
| +2% | +$12.9K | 0.01% | 540 |
|
|
2025
Q3 | $592K | Sell |
4,223
-131
| -3% | -$17.7K | 0.01% | 600 |
|
|
2025
Q2 | $547K | Buy |
4,354
+2,744
| +170% | +$342K | 0.01% | 594 |
|
|
2025
Q1 | $220K | Buy |
1,610
+290
| +22% | +$41.5K | 0.01% | 917 |
|
|
2024
Q4 | $202K | Sell |
1,320
-225
| -15% | -$38K | ﹤0.01% | 929 |
|
|
2024
Q3 | $299K | Sell |
1,545
-437
| -22% | -$91.4K | 0.01% | 758 |
|
|
2024
Q2 | $459K | Buy |
1,982
+156
| +9% | +$33.9K | 0.01% | 564 |
|
|
2024
Q1 | $394K | Sell |
1,826
-75
| -4% | -$17.6K | 0.01% | 603 |
|
|
2023
Q4 | $492K | Sell |
1,901
-33
| -2% | -$8.11K | 0.01% | 491 |
|
|
2023
Q3 | $497K | Sell |
1,934
-99
| -5% | -$26.5K | 0.02% | 463 |
|
|
2023
Q2 | $579K | Buy |
2,033
+42
| +2% | +$12.5K | 0.02% | 432 |
|
|
2023
Q1 | $554K | Sell |
1,991
-57
| -3% | -$15.8K | 0.02% | 441 |
|
|
2022
Q4 | $567K | Buy |
2,048
+291
| +17% | +$82.2K | 0.02% | 375 |
|
|
2022
Q3 | $469K | Sell |
1,757
-16
| -0.9% | -$3.4K | 0.02% | 402 |
|
|
2022
Q2 | $362K | Sell |
1,773
-79
| -4% | -$16.1K | 0.02% | 489 |
|
|
2022
Q1 | $391K | Sell |
1,852
-148
| -7% | -$32.2K | 0.02% | 495 |
|
|
2021
Q4 | $480K | Sell |
2,000
-192
| -9% | -$49.4K | 0.02% | 450 |
|
|
2021
Q3 | $620K | Buy |
2,192
+22
| +1% | +$7.21K | 0.03% | 352 |
|
|
2021
Q2 | $751K | Buy |
2,170
+197
| +10% | +$59.7K | 0.03% | 302 |
|
|
2021
Q1 | $552K | Sell |
1,973
-18
| -0.9% | -$4.85K | 0.03% | 328 |
|
|
2020
Q4 | $488K | Buy |
1,991
+148
| +8% | +$38.2K | 0.03% | 336 |
|
|
2020
Q3 | $523K | Buy |
1,843
+57
| +3% | +$15.9K | 0.03% | 296 |
|
|
2020
Q2 | $477K | Sell |
1,786
-725
| -29% | -$218K | 0.03% | 306 |
|
|
2020
Q1 | $794K | Buy |
2,511
+830
| +49% | +$252K | 0.06% | 178 |
|
|
2019
Q4 | $499K | Sell |
1,681
-235
| -12% | -$65.2K | 0.04% | 290 |
|
|
2019
Q3 | $446K | Buy |
1,916
+750
| +64% | +$175K | 0.04% | 288 |
|
|
2019
Q2 | $273K | Sell |
1,166
-209
| -15% | -$48.3K | 0.03% | 366 |
|
|
2019
Q1 | $325K | Sell |
1,375
-101
| -7% | -$31.8K | 0.04% | 297 |
|
|
2018
Q4 | $443K | Buy |
1,476
+80
| +6% | +$25.5K | 0.06% | 210 |
|
|
2018
Q3 | $492K | Buy |
1,396
+47
| +3% | +$16.2K | 0.06% | 208 |
|
|
2018
Q2 | $391K | Buy |
1,349
+220
| +19% | +$61.9K | 0.06% | 217 |
|
|
2018
Q1 | $309K | Buy |
1,129
+76
| +7% | +$23.6K | 0.05% | 246 |
|
|
2017
Q4 | $335K | Buy |
1,053
+44
| +4% | +$14.1K | 0.05% | 234 |
|
|
2017
Q3 | $319K | Buy |
1,009
+1
| +0.1% | +$296 | 0.05% | 236 |
|
|
2017
Q2 | $292K | Sell |
1,008
-110
| -10% | -$29.1K | 0.06% | 251 |
|
|
2017
Q1 | $303K | Sell |
1,118
-79
| -7% | -$22.3K | 0.06% | 225 |
|
|
2016
Q4 | $339K | Buy |
+1,197
| New | +$355K | 0.08% | 177 |
|
Other funds holding BIIB
VCM
VPM
Parallel Advisors's BIIB Position: Q1 2026 in Review
Parallel Advisors increased its Biogen (BIIB) stake by 1.5% in Q1 2026, buying an estimated $12K and bringing the position to 4,367 shares worth $801K. The position accounts for 0.01% of the portfolio, ranked #557.
Parallel Advisors first reported a position in BIIB in Q4 2016 and has held it in 38 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Parallel Advisors held 4,367 shares of Biogen worth $801K as of Q1 2026.
- Parallel Advisors bought 65 Biogen shares in Q1 2026, an estimated $12K.
- Biogen made up 0.01% of Parallel Advisors's portfolio in Q1 2026, its #557 holding.
- Parallel Advisors first reported a position in Biogen in Q4 2016 and has held it in 38 quarters since.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.